234 related articles for article (PubMed ID: 32642991)
1. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer.
Morimoto M; Arai T; Matsuura M; Ono Y
CEN Case Rep; 2021 Feb; 10(1):6-11. PubMed ID: 32642991
[TBL] [Abstract][Full Text] [Related]
2. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
4. [A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab].
Tomita M; Ochiai M; Shu S; Yamauchi Y; Shihara H; Ogata A; Fujisawa N; Yanai Y; Kamata T; Iehara N
Nihon Jinzo Gakkai Shi; 2014; 56(5):612-7. PubMed ID: 25130034
[TBL] [Abstract][Full Text] [Related]
5. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.
Hilburg R; Geara AS; Qiu MK; Palmer MB; Chiang EY; Burger RA; Hogan JJ
Clin Nephrol; 2021 Jul; 96(1):51-59. PubMed ID: 33896447
[TBL] [Abstract][Full Text] [Related]
7. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome.
Shimamura Y; Maeda T; Takizawa H
Clin Exp Nephrol; 2019 Jan; 23(1):142-143. PubMed ID: 29882112
[No Abstract] [Full Text] [Related]
9. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J
BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130
[TBL] [Abstract][Full Text] [Related]
10. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome.
Ozeki T; Tsuji M; Yamamoto J; Shigematsu C; Maruyama S
CEN Case Rep; 2018 Nov; 7(2):243-247. PubMed ID: 29766467
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report.
Endo Y; Negishi K; Hirayama K; Suzuki H; Shimizu A
Medicine (Baltimore); 2019 Nov; 98(45):e17870. PubMed ID: 31702653
[TBL] [Abstract][Full Text] [Related]
13. Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.
Liou AA; Skiver BM; Yates E; Persad P; Meyer D; Farland AM; Rocco MV
Am J Kidney Dis; 2019 May; 73(5):615-619. PubMed ID: 30528935
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.
Katagiri D; Hinoshita F
CEN Case Rep; 2018 Nov; 7(2):217-220. PubMed ID: 29766468
[TBL] [Abstract][Full Text] [Related]
15. A severe case of bevacizumab-induced thrombotic microangiopathy.
Bektas M; Samancı NS; Cokgezer S; Keskin D; Demirelli FH
J Oncol Pharm Pract; 2019 Oct; 25(7):1754-1757. PubMed ID: 30253727
[TBL] [Abstract][Full Text] [Related]
16. Progressive bevacizumab-associated renal thrombotic microangiopathy.
Uy AL; Simper NB; Champeaux AL; Perkins RM
NDT Plus; 2009 Feb; 2(1):36-9. PubMed ID: 25949282
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
18. Mesangial immunoglobulin A deposits in minimal change nephrotic syndrome: a report of an older patient and review of the literature.
Clive DM; Galvanek EG; Silva FG
Am J Nephrol; 1990; 10(1):31-6. PubMed ID: 2111636
[TBL] [Abstract][Full Text] [Related]
19. Nodular mesangial lesions, marked mesangiolysis, and fingerprint deposits of unknown origin in a patient with nephrotic syndrome: a unique combination of glomerular lesions.
Ohtani H; Wakui H; Komatsuda A; Okuyama S; Masai R; Maki N; Kigawa A; Sawada K
Clin Exp Nephrol; 2006 Jun; 10(2):140-5. PubMed ID: 16791402
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunopathologic study of mesangial IgM nephropathy: report of 41 cases.
Hsu HC; Chen WY; Lin GJ; Chen L; Kao SL; Huang CC; Lin CY
Histopathology; 1984 May; 8(3):435-46. PubMed ID: 6376323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
